Call for Abstract

World Liver Conference 2019, will be organized around the theme “Focusing on Healthy Future of Liver: Together Towards Tomorrow”

World Liver Conference 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in World Liver Conference 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Hepatitis B is a contagious and infectious disease of the liver caused by the Hepatitis B Virus (HBV), also known as serum hepatitis. The virus is classified under the hepadnaviridae family of viruses.

The symptoms of the disease do not develop until after a few weeks of exposure. Commonly, Hepatitis B is transmitted from an infected person's blood, semen, and to a lesser extent by other body fluids.

The global market is projected to display a growth represented by a CAGR of 5.30% by value during 2017 - 2022, chiefly driven by increase in healthcare spending and improving access to diagnosis for Chronic Hepatitis B, increasing risk of severe complications due to Hepatitis B virus.

Research and Markets - Hepatitis C is a blood-borne liver disease caused by the hepatitis C virus (HCV). HCV belongs to the Flaviviridaevirus family, and is a communicable disease spread primarily through direct contact with the blood or the bodily fluids of an infected individual, including sexual and mother-to-child transmission. Hepatitis C infection normally does not produce signs or symptoms and, as such, most people who are infected do not know they have the disease.

Hepatitis C virus affects between 130–150 million individuals every year globally of which approximately 700,000 people die. What is of greater concern is the fact that 15 to 20% of chronically infected patients develop liver cirrhosis or liver cancer.

It was estimated that there could be rise from $18700 million to $22721.1 million in hepatitis drug market by the end of forecasting period reflecting a sluggish CAGR of 3.3%.

The most widely recognized liver condition is Liver fibrosis and it is the imbalance of decay and synthesis of the extra cellular matrix (ECM) and collagens caused by necrosis and liver cell inflammation. Fibrosis is a procedure when connective tissue begins to proliferate in the portal parts. In a normal liver, 5.5 mg to 6.5 mg of collagen can be found in each gram of liver tissue.

Cirrhotic liver contains over 8.0 mg of collagen in every gram of liver tissue. It can also be higher than 20 mg. Liver fibrosis can be categorized into viral hepatitis fibrosis, parasitic infection fibrosis, alcoholic fibrosis, biliary fibrosis, intoxication fibrosis, cardiogenic fibrosis, and metabolic fibrosis. Immunologically, liver fibrosis can be categorized into two forms .i.e. passive fibrosis and active fibrosis. Viral hepatitis fibrosis is the most common form of liver fibrosis and is usually caused by chronic hepatitis C, B, and D. According to PubMed and scientific journal research, around 500 million people are affected by hepatitis B and C virus. Infected people develop chronic hepatitis, which leads to fibrosis. Liver fibrosis can cause major complications, including liver failure, portal hypertension, and liver cancer. The risk of liver cancer is greatly increased once fibrosis develops. Liver cancer is among the top ten causes of death globally. High alcohol consumption, fatty liver (steatosis), and insulin resistance increase the risk of liver fibrosis.

When we talk about region, then the world wide liver fibrosis drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for liver fibrosis drugs. In terms of revenue, the U.S. holds a major share of the liver fibrosis drugs market in North America. The market in Europe is expanding rapidly due to increase in the patient population in the region, especially in the U.K. and Germany. The market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing economies such as China and India are anticipated to contribute to the growth of the market in Asia Pacific between 2017 and 2025, due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increase in awareness among people in these countries.

This Session will cover the topics on other liver disease like - Alagille Syndrome, Alcohol-Related Liver Disease, Alpha-1 Antitrypsin Deficiency, Autoimmune Hepatitis, Benign Liver Tumors, Biliary Atresia, Cirrhosis, Galactosemia, Gilbert Syndrome, Hemochromatosis, Hepatitis A, Hepatitis B, Hepatitis C, Hepatic Encephalopathy, Intrahepatic Cholestasis of Pregnancy (ICP), Lysosomal Acid Lipase Deficiency (LAL-D), Liver Cysts, Liver Cancer, Newborn Jaundice, Non-Alcoholic Fatty Liver Disease, Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Reye Syndrome, Type I Glycogen Storage Disease, Wilson Disease.

This Track will cover the latest research findings regarding liver structure and function. This track will profit hepatologists, gastroenterologists, cell biologists, anatomists, toxicologists, and different other scientists interested in liver structure and function.

Liver transplant is a surgical procedure which is performed when the performing of the normal function of the liver fails like carbohydrates, proteins and fats. Most operations of liver transplant use deceased donor’s livers, though a liver may also come from another living person.

There are several disease conditions responsible for liver transplantations such as: Liver Cirrhosis, Cystic Fibrosis, Hemochromatosis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Wilson’s disease.

According To American Liver Foundation – around 1,500 people die every year in waiting for a donated liver to become available and according to the study, around 6,000 liver transplants are performed every year in U.S. and this number is increasing year by year. Around 17,000 adults and children’s in U.S. have been approved for liver transplantation and are awaiting for the donors to make liver available.

Market of Liver Transplantation is developing with a significant CAGR because of its high adoption rate as it is an effective modality for the administration of end-stage liver disease. Developing countries are growing with a slower CAGR compared to other parts of the world.

When liver become inflamed because of virus or other infection agent then it is called as Inflamed Liver and it is one of the common liver diseases.

Liver Inflammation is an early stage of the liver disease and liver inflammation is visible when our body tries to fight against an infection. And when the largest part of our body will become inflamed, then that time the area become hot and painful. But this type of symptoms does not shown by inflamed liver. Liver inflammation can be removed if it is diagnosed and treated successfully.

Liver Cancer, also known as hepatic cancer or primary liver cancer, is a cancer which starts in the cells of the liver. The most common form is hepatocellular carcinoma (HCC) which originates from hepatocytes, the most abundant cell type in the liver, although other cell types in the liver can also become cancerous.

In 2017, according to the American Cancer Society, there would be 29,000 cases of cancer death in US. From the mid-1970s, the liver cancer incidence has been rising in the United States and it is expected to grow till 2030.

The fifth most prevalent cancer across the globe is Liver Cancer and is responsible for 9.0% of all cancer deaths. 782,451 new cases of liver cancer were diagnosed in 2012. And 745,533 deaths were reported because of liver cancer. Liver cancer is considered to be an important public health issue because of its extremely aggressive nature and very poor survival rate.

This track will focus on children’s with liver disease and also multidisciplinary approach to diagnosis and management of pediatric liver disease.

Drugs are an important reason for liver injury. Liver injury occurs because of use of more than 900 drugs, toxins, and herbs and drugs represent 20 – 40 percent of all instances of fulminant liver failure. Around 75 percent of the idiosyncratic drug reactions will leads to transplantation of liver or even death sometimes. Drug Hepatotoxicity is the most common reason for withdrawal of an approved drug. Doctors must be vigilant in recognizing drug-related liver injury as because if it will be detected earlier, then it could decrease the severity of hepatotoxicity if the drug is discontinued. The illustrations of DILI are highly variable, ranging from asymptomatic elevation of liver enzymes to fulminant liver failure. Information on commonly implicated agents and a high index of suspicion are very much essential in diagnosis.     

In U.S.A., around 200 cases of acute liver failure occur every year and drugs account for over 50% of them (39% are because of acetaminophen, 13% are idiosyncratic reaction because of other meds). Drugs accounts for 2-5% of cases of patients who all are hospitalized with jaundice and around 10% of all cases of acute hepatitis.

Hepatitis C virus (HCV) is a disease that infects the liver. Lifelong infection can be caused by HCV, and after some time, it can cause fibrosis (mild to moderate liver scarring), cirrhosis (serious liver scarring), liver cancer, liver failure and death.

Hepatitis C is common among individuals living with HIV. The people who all are living with HIV, Hepatitis C is very common among them. This means that about 225,000 to 330,000 people in the United States are living with both viruses.

HIV can worsen hepatitis C. HIV can increase the risk of liver damage and also can speed up the onset of liver damage following infection. People who al are affected by HIV should work closely with their health care providers so as to avoid and treat both condition.

The growth of the liver which generally occur after liver damage or partial hepatectomy is a well-known phenomenon in the wide field of hepatology.

While liver repair may involve repair mechanisms also observed in other organs, it is characteristic of the liver to generate the previous organ mass after partial hepatectomy in aa very short time.

The mechanisms involved in liver repair on the other hand and in liver regeneration on the other hand have been studied extensively. Research has focused on the biology of the two processes and in particular on the mediators released from the injured organ to initiate repair as well as liver growth.

Imaging of the liver is undertaken for the detection and characterization of suspected primary or secondary neoplasms, prior to planning a surgery or chemotherapy pump placement, for assessing treatment response, for evaluating biliary pathology, and for screening for liver neoplasms in high-risk groups. In this article, we review the advantages and disadvantages of various imaging modalities in the evaluation of the liver and formulate guidelines for the imaging of common clinical indications. A brief review of imaging findings in focal and diffuse liver disease is also presented.

Liver, biliary tract, gallbladder imaging tests incorporate ultrasonography, endoscopic retrograde cholangiopancreatography, computed tomography, radionuclide scanning, percutaneous transhepatic cholangiography, magnetic resonance imaging, simple x-rays and operative cholangiography.

In coming years, it is expected that worldwide Liver Biopsy market will advance with higher growth rate when we compare it with previous years. Rising pressure to control healthcare costs has fuelled the development of the market for Liver Biopsy Market. The global liver biopsy market is expected to grow at a CAGR of 4.2% during the forecast period 2017-2023.